# Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients

> **NCT00170833** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 80 (—)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00170833
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2005-11
- **Final completion:** —
- **Target enrollment:** 80 (—)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170833, "Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00170833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*